Imagion Biosystems Limited (Company) is committed to the objective of promoting investor confidence and the rights of shareholders.
Read the Imagion Biosystems Limited Disclosure and Communication Policy.
Imagion Biosystems Limited Disclosure and Communications Policy
Highlights: Announced preliminary performance of MagSense® HER2 Imaging Agent in phase 1 study after study closure (post quarter end) Entered a strategic partnership with Prestige
Transforming medical imaging for early disease detection
We’re on a mission to make cancer more detectable.